Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876—A Less Toxic and More Potent Analogue of Bedaquiline

Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876—A Less Toxic and More Potent Analogue of Bedaquiline

Bedaquiline is a novel drug approved in 2012 by the FDA for treatment of drug-resistant tuberculosis (TB). Although it shows high efficacy towards drug-resistant forms of TB, its use has been limited by the potential for significant side effects. In particular, bedaquiline is a very lipophilic compo...

Full description

Bibliographic Details
Main Authors: Peter J. Choi, Daniel Conole, Hamish S. Sutherland, Adrian Blaser, Amy S.T. Tong, Christopher B. Cooper, Anna M. Upton, Brian D. Palmer, William A. Denny
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Molecules
Subjects:
bedaquiline
tmc207
sirturo
bedaquiline analogues
tbaj-876
mycobacterium tuberculosis
tuberculosis
drug development
Online Access:https://www.mdpi.com/1420-3049/25/6/1423

Internet

https://www.mdpi.com/1420-3049/25/6/1423

Similar Items